- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
U.S. Patent Office allows Mylan to go after half a dozen patents tied to Allergan's dry eye franchise Restasis.
The drugmaker is down nearly 46% year to date, which has created a great buying opportunity.
Wait for a bounce and then a retest before stepping up to buy.